Previous studies have reported that blocking Dll-4-Notch signaling in animal models of experimental autoimmune encephalomyelitis and asthma decreased both Th17 response and clinical symptoms severity (Weng et al., 2017; Bassil et al., 2011). This evidence concerns the gene DLL4 and experimental autoimmune encephalomyelitis.